A. Ganesan


  • 1.50 Chemistry

If you made any changes in Pure these will be visible here soon.

Personal profile


ResearcherID profilehttp://www.researcherid.com/rid/F-6698-2011

PhD Positions

Click here for current PhD opportunities in PHA. But feel free to email me to discuss projects outside these areas and alternative sources of funding.

Ganesan obtained a BSc (Hons) in Chemistry at the National University of Singapore (1986). He completed his PhD in synthetic methodology and total synthesis under the supervision of Clayton Heathcock at the Department of Chemistry, University of California-Berkeley (1992) and was subsequently a postdoctoral fellow with Gregory Verdine at the Department of Chemistry at Harvard University. In 1993, he joined the Institute of Molecular and Cell Biology in Singapore as a Senior Research Chemist at the Centre for Natural Product Research and in 1996 became Principal Investigator of the Institute’s Medicinal and Combinatorial Chemistry group. In 1999 he joined the University of Southampton as a Reader in the Combinatorial Chemistry Centre for Excellence. In 2011 he became the Chair of Chemical Biology at UEA’s School of Pharmacy. He is Director of Postgraduate Research and Head of the Healthy Ageing research theme within the School. 

Ganesan is co-founder of the biotech company Karus Therapeutics and Chair of the EU COST Action CM1406, 'Epigenetic Chemical Biology'. He sits on the IUPAC Subcommittee for Medicinal Chemistry and Drug Development and the Royal Society of Chemistry's Bioorganic & Medicinal Chemistry Sector committee.

Ganesan's research centres around chemical biology, medicinal chemistry and organic synthesis with an emphasis on biologically active natural products and epigenetics.

Selected publications

Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore

Davidson, S. M.; Foote, K.; Kunuthur, S.; Gosain, R.; Tan, N.; Tyser, R.; Zhao, Y. J.; Graeff, R.; Ganesan, A.; Duchen, M. R.; Patel, S.; Yellon, D. M.
Cardiovasc. Res. 2015, 108, 357–366.
DOI: 10.1093/cvr/cvv226

Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase
Tortorici, M.; Borrello, M. T.; Tardugno, M.; Chiarelli, L. R.; Pilotto, S.; Ciossani, G.; Vellore, N. A.; Bailey, S. G.; Cowan, J.; O’Connell, M.; Crabb, S. J.; Packham, G.; Mai, A.; Baron, R.; Ganesan, A.; Mattevi, A. 
ACS Chem. Biol. 2013, 8, 1677–1682.
DOI: 10.1021//cb4001926

Total Synthesis and Stereochemical Assignment of Burkholdac B, a Depsipeptide HDAC Inhibitor
Benelkebir, H.; Donlevy, A. M.; Packham, G.; Ganesan, A
Org. Lett. 2011, 13, 6334–6337.
DOI: 10.1021/ol202197q

Determination of Molecular Torsion Angles Using Nuclear Singlet Relaxation
Tayler, M. C. D.; Marie, S.; Ganesan, A.; Levitt, M. H.
J. Am. Chem. Soc. 2010, 132, 8225–8227.
DOI: 10.1021/ja1012917

Identification of a Chemical Probe for NAADP by Virtual Screening
Naylor, E.; Arredouani, A.; Vasudevan, S. R.; Lewis, A. M.; Parkesh, R.; Mizote, A.; Rosen, D.; Thomas, J. M.; Izumi, M.; Ganesan, A.; Galione, A.; Churchill, G. C.
Nat. Chem. Biol. 2009, 5, 220-226.
DOI: 10.1038/nchembio.150

Key Research Interests

Cancer Research UK
Histone Methylation Inhibitors
G. Packham (U. Southampton) and A. Ganesan

NAADP Receptor Antagonists
A. Gansan

Areas of Expertise

Medicines and health; discovery of new drugs; epigenetics - effect of genetics versus environment on health; organic chemistry; chemical biology.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or